133 related articles for article (PubMed ID: 34748277)
1. Reply to comment on "Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma".
Takahashi D; Mizuno T; Ebata T
J Hepatobiliary Pancreat Sci; 2022 Apr; 29(4):e29. PubMed ID: 34748277
[No Abstract] [Full Text] [Related]
2. Comment on "Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma".
Mungmungpuntipantip R; Wiwanitkit V
J Hepatobiliary Pancreat Sci; 2022 Apr; 29(4):e28. PubMed ID: 34748290
[No Abstract] [Full Text] [Related]
3. Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma: A propensity score-adjusted analysis.
Takahashi D; Mizuno T; Yokoyama Y; Igami T; Yamaguchi J; Onoe S; Watanabe N; Maeda O; Ando M; Ebata T
J Hepatobiliary Pancreat Sci; 2021 Sep; 28(9):716-726. PubMed ID: 34087061
[TBL] [Abstract][Full Text] [Related]
4. Complete response of recurrent perihilar cholangiocarcinoma following sintilimab combined with lenvatinib plus S-1: a case report and review of literature.
Liu QQ; Yu XH; Tang QB; Chen D; Zhang R; Liu C; Shi XD
Anticancer Drugs; 2024 Jan; 35(1):81-85. PubMed ID: 37227031
[TBL] [Abstract][Full Text] [Related]
5. Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.
Jeong H; Yoo C;
Hepatology; 2023 Oct; 78(4):E74-E75. PubMed ID: 37459559
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of systemic induction therapy in initially unresectable locally advanced intrahepatic and perihilar cholangiocarcinoma: A systematic review.
Belkouz A; Nooijen LE; Riady H; Franken LC; van Oijen MGH; Punt CJA; Erdmann JI; Klümpen HJ
Cancer Treat Rev; 2020 Dec; 91():102110. PubMed ID: 33075684
[TBL] [Abstract][Full Text] [Related]
7. Reply to comment on "surgical implications of the confluence patterns of the left intrahepatic bile ducts in right hepatectomy for perihilar cholangiocarcinoma".
Hosokawa I; Ohtsuka M
J Hepatobiliary Pancreat Sci; 2023 Feb; 30(2):e7-e8. PubMed ID: 35975954
[No Abstract] [Full Text] [Related]
8. Letter to the Editor: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.
Hu YF; Gu HF; Jin YW; Li FY
Hepatology; 2023 Oct; 78(4):E72-E73. PubMed ID: 37459557
[No Abstract] [Full Text] [Related]
9. [Long-Term Survival after Surgery with Postoperative Chemotherapy for Perihilar Cholangiocarcinoma with Residual Invasive Carcinoma at Ductal Resection Margins-A Case Report].
Oiwa T; Miura K; Sakata J; Yuza K; Toge K; Hirose Y; Takizawa K; Ichikawa H; Hanyu T; Nakano M; Nagahashi M; Shimada Y; Ishikawa T; Kobayashi T; Wakai T
Gan To Kagaku Ryoho; 2020 Dec; 47(13):1899-1901. PubMed ID: 33468866
[TBL] [Abstract][Full Text] [Related]
10. Repetitive response to gemcitabine that led to curative resection in cholangiocarcinoma.
Kim SH; Kim IH; Kim SW; Lee SO
World J Gastroenterol; 2009 Sep; 15(36):4593-5. PubMed ID: 19777621
[TBL] [Abstract][Full Text] [Related]
11. [Klatskin tumor - a case report].
Iwaniec-Karlikowska E; Augustyn M; Grys I
Pol Merkur Lekarski; 2016 Feb; 40(236):107-9. PubMed ID: 27000815
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant gemcitabine monotherapy for resectable perihilar cholangiocarcinoma with lymph node involvement: a propensity score matching analysis.
Mizuno T; Ebata T; Yokoyama Y; Igami T; Sugawara G; Yamaguchi J; Nagino M
Surg Today; 2017 Feb; 47(2):182-192. PubMed ID: 27194019
[TBL] [Abstract][Full Text] [Related]
13. [A long-term survival case of unresectable intrahepatic cholangiocarcinoma treated with chemotherapy].
Tamura T; Mizuyama Y; Shinto O; Nishihara T; Nakagawa H; Ono Y
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2732-4. PubMed ID: 21224695
[TBL] [Abstract][Full Text] [Related]
14. Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma-Reply.
Cercek A; Jarnagin WR
JAMA Oncol; 2020 Jun; 6(6):935-936. PubMed ID: 32271367
[No Abstract] [Full Text] [Related]
15. Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience.
Polistina FA; Guglielmi R; Baiocchi C; Francescon P; Scalchi P; Febbraro A; Costantin G; Ambrosino G
Radiother Oncol; 2011 May; 99(2):120-3. PubMed ID: 21621289
[TBL] [Abstract][Full Text] [Related]
16. Haemolytic uremic syndrome and gemcitabine: jaundice is not always progression in cholangiocarcinoma.
Crouzet L; Edeline J; Le Du F; Boucher E; Audrain O; Raoul JL
Acta Oncol; 2012 May; 51(5):687-8. PubMed ID: 22356625
[No Abstract] [Full Text] [Related]
17. No-Touch Concept Is Invalid for Left-Dominant Perihilar Cholangiocarcinoma.
Ji G; Wang K; Li X
J Gastrointest Surg; 2018 Mar; 22(3):558-559. PubMed ID: 29340919
[No Abstract] [Full Text] [Related]
18. Intrahepatic cholangiocarcinoma with sarcomatous change producing granulocyte-colony stimulating factor.
Takenaka M; Akiba J; Kawaguchi T; Niizeki T; Arinaga-Hino T; Sata M; Nakashima O; Yano H; Kage M
Pathol Int; 2013 Apr; 63(4):233-5. PubMed ID: 23692426
[No Abstract] [Full Text] [Related]
19. [Long-surviving patient with hilar cholangiocarcinoma by gemcitabine monotherapy].
Iwata N; Yoshida T; Katsuta E; Aoyagi H; Takahata T; Hasegawa K; Kaneko J; Maejima S
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2116-8. PubMed ID: 23267995
[TBL] [Abstract][Full Text] [Related]
20. [Interdisciplinary diagnosis of and therapy for cholangiocarcinoma].
Kolligs FT; Zech CJ; Schönberg SO; Schirra J; Thasler W; Graeb C; Beuers U; Wilkowski R; Jacobs T; Böck S; Berster J; Heinemann V; Schäfer C
Z Gastroenterol; 2008 Jan; 46(1):58-68. PubMed ID: 18188818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
